

## Special Issue

# Acute Leukemia in Older Adults - Is a Cure Possible?

### Message from the Guest Editor

Prognosis of acute leukemia has seen substantial improvements this last decade. Most of these advances came from better risk stratification and improved allogeneic transplant procedures. New therapeutics such as bispecific antibodies, TKI and IDH inhibitors, BH3 mimetics, and CAR-T cells will certainly improve prognosis in the coming years, but long-term follow-up is needed to firmly establish clinical benefits, notably for elderly patients. For this category of patient, little improvement has been seen. Recent publications have shed light of the high prevalence of age-related clonal hematopoiesis in the common population and the specific risk of myeloid malignancies conferred by specific mutation, variant allele frequency, and clonal dynamics. This Special Issue of *Cancers* therefore encompasses new research articles and timely reviews on all aspects of acute leukemia and clonal evolution in elderly patients.

---

### Guest Editor

Prof. Dr. Bruno Quesnel

Department of Hematology, CHU Lille, F-59000 Lille, France

---

### Deadline for manuscript submissions

closed (15 April 2021)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 8.0  
Indexed in PubMed



[mdpi.com/si/57032](https://mdpi.com/si/57032)

*Cancers*

MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 8.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)